Welcome to our dedicated page for Cryo-Cell Intl news (Ticker: CCEL), a resource for investors and traders seeking the latest updates and insights on Cryo-Cell Intl stock.
Cryo-Cell International, Inc. (CCEL) is a NYSE American–listed company focused on cellular processing, cryogenic storage, and cord blood banking. The company describes itself as the world’s first private cord blood bank to separate and store stem cells, with operations that span private cord blood and cord tissue banking, a public cord blood banking program in partnership with Duke University, and technology and biostorage offerings such as PrepaCyte-CB and ExtraVault.
This news page aggregates company-issued updates and regulatory disclosures that affect Cryo-Cell’s business and capital structure. Readers can follow periodic financial results, where the company breaks out revenue from processing and storage fees, public banking activities, and product revenue. Dividend-related announcements are also a recurring theme, including the initiation of regular quarterly cash dividends, changes in dividend levels, and decisions not to declare dividends in certain quarters, often linked to profitability, capital requirements, and strategic priorities.
In addition to earnings and dividend news, Cryo-Cell’s releases highlight developments tied to its license agreement with Duke University, research and development spending related to clinical studies and manufacturing capabilities, and the launch and positioning of ExtraVault for biostorage and distribution services. Disclosures about strategic reviews, such as the pause of initiatives relating to a possible sale or merger of the company, provide further context on corporate strategy.
Investors and observers who want to monitor how Cryo-Cell’s cord blood banking operations, cellular therapy ambitions, and biostorage services evolve over time can use this page to review a chronological record of earnings releases, dividend decisions, strategic updates, and other material announcements.
Cryo-Cell International has announced plans for its Institute for Cellular Therapies after securing an exclusive license from Duke University. This partnership provides commercial rights to a range of FDA regulatory data and intellectual property related to cord blood and cord tissue-derived cell therapies that passed Phase 1/Phase 2 trials. The company aims to conduct further Phase 2 and Phase 3 trials focusing on conditions like hypoxic ischemic encephalopathy, cerebral palsy, and autism. Successful trials could lead to FDA licensure and commercialization.
On October 15, 2021, Cryo-Cell International (CCEL) reported Q3 2021 results, showing revenue of $7.5 million, an 8% decline from $8.1 million in Q3 2020. Processing and storage fees contributed $7.3 million. Net income was $857,000 ($0.10 per share), up from $784,000 in the prior year. Expenses increased, primarily due to costs related to the Cryo-Cell Institute and patent expenses. Despite revenue decline, the company emphasized solid results amid its transition to a vertically integrated cellular therapy entity.
Cryo-Cell International, Inc. (Nasdaq:CCEL) has appointed Mark Portnoy and Daniel Mizrahi to its Board of Directors, following the resignations of George Gaines and Jonathan Wheeler, M.D. Gaines retires while Wheeler steps down for health reasons. Both new appointees bring extensive experience, with Portnoy having previously served on the board and Mizrahi leading a manufacturing company in Guatemala. The board expects to enhance shareholder value, particularly after the recent NASDAQ uplisting and a transformative agreement with Duke University.
Cryo-Cell International, Inc. (CCEL) has announced its common stock is listed on the Nasdaq Capital Market as of August 31, 2021. This milestone marks an achievement in meeting Nasdaq's stringent requirements and aims to enhance liquidity and broaden the shareholder base. Chairman David Portnoy expressed optimism that this uplisting will reduce the valuation gap between market and intrinsic value. Cryo-Cell is transitioning into a biopharmaceutical company, providing experimental treatments at the upcoming Cryo-Cell Institute for Cellular Therapies.
Cryo-Cell International (CCEL) has acquired an 8,326 sq. ft. facility in Durham, NC, for its Institute for Cellular Therapies, strategically located near the Raleigh-Durham International Airport. The clinic aims to provide FDA-approved clinical trials for patients in need of cord blood therapies by early 2022. This facility will employ advanced technology and child-friendly layout while adhering to COVID safety guidelines. The treatments target various conditions, including autism spectrum disorders and cerebral palsy.
Cryo-Cell International, the world’s first cord blood bank, announced that Chairman and Co-CEO, David Portnoy, will present at the Q3 Virtual Investor Summit on August 18, 2021, at 2:45 PM EDT. The 30-minute session will include a 20-minute corporate overview followed by a 10-minute Q&A. In February 2021, Cryo-Cell transformed into a vertically integrated cellular therapy company through a license agreement with Duke University, set to treat patients at its first infusion clinic opening in early 2022. The event can be accessed via registration.
Cryo-Cell International, Inc. (CCEL) reported its fiscal Q2 2021 results with a revenue decrease of 8% to $7.21 million, down from $7.87 million in Q2 2020. The company generated $7.16 million in processing and storage fees. Net income rose to $1.17 million, or $0.15 per basic share, from $953,000, or $0.13 per basic share in the prior year. Cost reductions in sales and administrative expenses contributed to net income growth despite lower revenues. Cryo-Cell continues to expand its operations and maintain quality standards with FDA registration and AABB accreditation.
Cryo-Cell International is conducting two pivotal clinical studies: MASC for COVID-19 related Acute Respiratory Distress Syndrome and MISTIC for children with Multisystem Inflammatory Syndrome associated with COVID-19. MASC has completed Phase 1 and is enrolling for Phase 2, while MISTIC is in Phase 1 enrollment. Both studies utilize human cord tissue derived mesenchymal stromal cells. The ongoing research underscores Cryo-Cell's commitment to advancing regenerative medicine and improving patient outcomes amid the ongoing pandemic.
Cryo-Cell International, Inc. (OTC: CCEL) reported its fiscal first quarter results for 2021, citing revenues of $6.86 million, a decrease from $7.62 million in Q1 2020. The revenue comprised $6.74 million from processing and storage fees, $38,000 from product sales, and $84,000 from public banking. Net income was approximately $694,000, consistent with the prior year. The company is optimistic about future opportunities tied to its licensing agreement with Duke University, despite challenges posed by the COVID-19 pandemic affecting birth rates.
Cryo-Cell International, Inc. (CCEL) has entered a collaborative licensing agreement with Duke University to utilize proprietary processes and regulatory data pertaining to cord blood and tissue. This agreement allows Cryo-Cell to explore potential treatments for conditions with limited FDA approved therapies, including cerebral palsy, autism, multiple sclerosis, and COVID-19. Cryo-Cell is focusing on expanding its core business units, including biopharmaceutical manufacturing, pending necessary FDA approvals. The partnership raises the possibility of uplisting the stock to NASDAQ.